Clinical Research Training in Hematology Hall of Fame

Translational Research Training in Hematology Hall of Fame

Publication of EHA Annual General Meeting 2024 minutes

The 2024 EHA Annual General Meeting (AGM) took place in the vibrant city of Madrid, Spain, on June 14, 2024. Scheduled on Friday during the EHA Annual Congress, the meeting was once more in a hybrid format.

Congress Sponsor Program

Join us at the EHA Annual Congress, where you have the unique opportunity to connect and grow with a community of hematology experts.

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease

November 10-11, 2022 | Bordeaux, France

Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.